-
Janssen's potential "first-in-class" bispecific antibody is clinically approved in China
Time of Update: 2021-09-13
Text|Pharmaceutical Mission HillsThe Center for Drug Evaluation (CDE) of the National Medical Products Administration of China revealed that the Class 1 new drug, talquetamab injection, declared by Johnson & Johnson's Janssen company, has obtained the implied license for clinical trials and is intended to be developed for multiple bone marrow.
-
AstraZeneca fulvestrant and CDK4/6 inhibitor combination therapy approved in China
Time of Update: 2021-09-13
Source: Guanlan PharmaceuticalOn the evening of August 27th, AstraZeneca China announced that the National Medical Products Administration (NMPA) of China has officially approved the combined treatment of fulvestrant injection (fulvestrant) and the CDK4/6 inhibitor abexili, which is suitable for Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer is used for patients who have experienced disease progression after receiving endocrine therapy .
-
Soaring 223.21%!
Time of Update: 2021-09-13
As an established pharmaceutical company, Fosun Pharma's generic drugs are also facing the impact of centralized procurement, and innovative products have become a strong "blood transfusion" support .
In the first half of the year, the sales revenue of Fosun Pharma's anti-tumor and immunomodulation core products increased by 256.
-
State Food and Drug Administration: Olympus, Braun Medical and other four companies actively recalled medical devices
Time of Update: 2021-09-13
voluntarily recalled the electronic bronchoscope (registration number: National Food and Drug Administration (Jin) 2006 No.
Braun Surgical SA voluntarily recalls Monosyn Synthetic absorbable surgical sutureBraun Medical Spain Joint Stock Company B.
Braun Surgical SA voluntarily recalls Monosyn Synthetic absorbable surgical sutureBraun Medical (Shanghai) International Trade Co.
-
The sales myth of new crown drugs
Time of Update: 2021-09-13
The net profit of the new crown vaccine reached 34-40 billion yuan; Fosun Pharma's revenue in the first half of the year was 500 million yuanWith such attractive market returns, the development of new crown therapeutic drugs on a global scale is naturally in full swing, including vaccines, neutralizing antibodies, and oral drug projects of many Chinese companies are also accelerating to the goal of phase III and listing .
-
Performance comparison of Chinese medicine giants: Donge Ejiao, Yunnan Baiyao, Pien Tze Huang...
Time of Update: 2021-09-13
Up to now, the four time-honored traditional Chinese medicine brands, Yunnan Baiyao, Donge Ejiao, Pien Tze Huang, and Tong Ren Tang have all released their 2021 semi-annual reports .
-
New progress has been made in the research on the defense mechanism of tea pests after feeding
Time of Update: 2021-09-13
228)" Herbivore-induced volatiles influence moth preference byRecently, the research group of Professor Song Chuankui of the State Key Laboratory of Tea Biology and Resource Utilization of Anhui Agricultural University and the research group of Researcher Sun Xiaoling of the Tea Research Institute of the Chinese Academy of Agricultural Sciences jointly published the title "Plant, Cell & Environment (Impact Factor 7.
-
The State Food and Drug Administration allows "Journal of Alzheimer's Disease and Related Diseases" to publish prescription drug advertisements
Time of Update: 2021-09-13
On August 25, the State Food and Drug Administration issued a notice agreeing to include the "Journal of Alzheimer's Disease and Related Diseases" in the list of medical and pharmaceutical professional publications that allow the publication of prescription drug advertisements .
-
The latest development of the "Hong Kong and Macau Medicines and Equipment Links"!
Time of Update: 2021-09-13
Medical News, August 31, August 27, Guangdong Provincial Food and Drug Administration and Guangdong Provincial Health Commission held a special press conference . Su Shengfeng, a member of the Part
-
Research progress has been made on the role of genes and environmental factors in the processing of large and small illusions
Time of Update: 2021-09-13
In the early visual cortex, genes can explain about 39% of the variation in neural activity related to the overestimated component of the size illusion (the target circle is surrounded by a group of small circles) .
-
Kelun re-attacked the second production of inhalants is this 1 billion variety
Time of Update: 2021-09-13
According to data from Mi Nei. com, in 2019, the sales scale of terbutaline sulfate nebulized inhalation solution in China's public medical institutions has exceeded 1.
-
2022 Shanghai New Energy Logistics Auto Show, Leading Green City Travel
Time of Update: 2021-09-13
2022 Shanghai New Energy Logistics Auto Show, Leading Green City TravelThe General Office of the State Council has issued the "New Energy Automobile Industry Development Plan (2021-2035)", which clearly requires that from 2021, the national ecological civilization pilot zone and the key areas for air pollution prevention and control will add or update public vehicles, rentals, logistics and distribution and other public domain vehicles.
-
The Gansu Provincial Food and Drug Administration issued 52 Chinese medicine processing specifications including ghost arrow feathers and mugwort leaves
Time of Update: 2021-09-13
, have been reviewed by the Gansu Provincial Drug Administration, reviewed by the Gansu Provincial Drug Inspection and Research Institute, and technically reviewed by the expert group, drafted standards and regulations, and the content is complete.
-
The second shot of the collection of consumables is about to fire! Will the average drop of these four types of products exceed 80%?
Time of Update: 2021-09-13
Can domestically produced substitutes be successfully realized through centralized procurement?In order to better promote the centralized procurement of artificial joints, on August 26, the State Organization of the Joint Procurement Office of High-Value Medical Consumables conducted a training meeting for participating companies to interpret and answer questions on the procurement documents .
-
Better than approved therapy Pfizer JAK1 inhibitor for eczema to reach phase 3 clinical endpoint
Time of Update: 2021-09-13
On August 30, 2021, Pfizer announced that the Phase 3 clinical trial of the oral JAK1 inhibitor abrocitinib, JADE DARE, has reached its common primary and critical secondary efficacy endpoints .
-
New changes in the drug treatment pattern of primary hyperparathyroidism in the post-epidemic era
Time of Update: 2021-09-13
Among them, calcitriol, as the first choice for vitamin D supplementation, became the "pillar" of the PHPT therapeutic market, 2012 The annual revenue of 340 million yuan is arrogant, which is basically equivalent to the combined market share of alfacalcidol and salmon calcitonin.
-
National Medical Insurance Bureau: The list of public service items for the collection of medical consumables is here
Time of Update: 2021-09-13
On August 30, 2021, the National Medical Insurance Administration issued the "Notice on Printing and Distributing the List of Public Service Items for the Centralized Procurement of Medicines and Medical Consumables", requiring all provinces to complete the guidelines according to the list before the end of December 2021.
-
Well-known chain pharmacies lay out convenience stores
Time of Update: 2021-09-13
According to the annual report data, Jianzhijia has 240 convenience stores in 2020, which is 13% of the number of pharmacies in the same period; the average daily efficiency is 44.
-
China Food and Drug Administration: Xingye Pharmaceutical and Zhongjian Medical Devices are recalling a batch of medical devices
Time of Update: 2021-09-13
On August 30, the State Food and Drug Administration issued an announcement to notify Xingye Pharmaceutical and Zhongjian Medical Devices of the voluntary recall of some of their products in violation of regulations .
actively recalls disposable medical masksAnhui Xingye Pharmaceutical Technology Co.
-
Large numbers of medical representatives are becoming more and more difficult
Time of Update: 2021-09-13
The filing system positions the work of medical representatives as academic promotion, requiring medical representatives to no longer undertake sales tasks, and at the same time not to carry out in-hospital promotion activities without permission .
